HIV Research Highlights from First Day of CROI 2018

Date: 03/06/2018

Publication:

NIH/NIAID Website

. . . Short-course regimen for TB prevention—A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. These findings could be a “game changer” for helping people stay TB-free, remarked Dr. Dieffenbach, noting that TB is the single biggest killer of HIV+ people around the globe. Adults and adolescents in the trial were more likely to complete the short-course regimen—consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks—than the standard nine-month regimen of daily isoniazid, according to the findings presented by Richard Chaisson, MD, of Johns Hopkins. The study was sponsored by NIAID and conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Read the study abstract; read NIAID’s news release about this research . . . 

Access Full Article

Clinical Trials

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More